Shikonin has been shown to alleviate excessive Th2 cell activation in rat models of allergic rhinitis by reducing the expression of co-stimulatory molecules CD80 and CD86 on dendritic cells (Liu and You, 2016) while concurrently reducing the circulating levels of IL-4 in peripheral blood (Li and You, 2018). Here, IL4 is linked to allergic rhinitis.